Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Glioblastoma 77Prostatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 50Breast Neoplasms 49Esophageal Neoplasms 47Rectal Neoplasms 41Lung Neoplasms 40Squamous Cell Carcinoma of Head and Neck 32Gliosarcoma 31Head and Neck Neoplasms 30Brain Neoplasms 30Pancreatic Neoplasms 29Uterine Cervical Neoplasms 27Neoplasm Metastasis 23Glioma 23Neoplasms 22Oropharyngeal Neoplasms 20Esophageal Squamous Cell Carcinoma 20Sarcoma 19Melanoma 18Astrocytoma 17Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11Burkitt Lymphoma 10

Interventions

HhAntag691 21Biopsy 11Imiquimod 10Aminolevulinic Acid 9sonidegib 8Photochemotherapy 8Nivolumab 81-phenyl-3,3-dimethyltriazene 7methyl 5-aminolevulinate 6cemiplimab 6Surgical Procedures, Operative 5Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Mohs Surgery 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Tomography, Optical Coherence 3Standard of Care 3Niacinamide 3Microscopy, Confocal 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Basal Cell × Radiation × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡